Agios Pharmaceuticals (AGIO) shares surged 11.2% this week, buoyed by a positive first-quarter earnings report that highlighted the successful U.S. launch of Aqvesme. The company reported sales growth from $8.7 million to $20.7 million year-over-year, driven by strong demand for its recently approved treatments for hemolytic anemia and thalassemia. Agios also provided updates on its pipeline, particularly mitapivat for sickle cell disease (SCD) and tebapivat for lower-risk myelodysplastic syndromes.
Despite a recent setback from competitor Novo Nordisk, which reported superior results for its SCD treatment, Agios remains optimistic. Management is on track with the FDA for an accelerated approval pathway for mitapivat in SCD, with expectations for a filing in Q2. Additionally, Phase 2 results for tebapivat are anticipated in 2026, adding to the company’s growth narrative.
For market professionals, Agios presents a compelling case of resilience and potential, especially with its promising pipeline and the positive trajectory of Aqvesme sales.
Source: fool.com